Identify Therapies that
will Slow, Stop, or Reverse
the Progression of
The NDC is a consortium uniting the best and the brightest leading scientists with a seasoned drug development team with a singular mission to defeat neurodegeneration.
The multi-disciplinary team will include researchers from Baylor College of Medicine, the Massachusetts Institute of Technology and the University of Texas MD Andersons Cancer Center’s Institute for Applied Cancer Science (IACS).
The aim is to better understand the underlying biology of Alzheimer’s disease and translate this knowledge into therapeutic interventions that can effectively alleviate symptoms by delaying, reversing and/or eliminating the pathology of the disease.
The gift is contingent on consortium partners raising an additional $25 million by January 2016.
The aim of the collaboration is to identify and develop novel small molecule modulators of an undisclosed G-protein coupled receptor linked to Alzheimer’s disease.